1 Global Liquid Biopsy Products Market Insight Analysis
The total value of the global Liquid Biopsy Products Market will reach US$2,756.05 million in 2024, with a CAGR of approximately 22.83% from 2024 to 2033.
Liquid Biopsy Products generally refers to the detection of circulating tumor cells (CTC), circulating tumor DNA (ctDNA), circulating exosomes, and other analytes in body fluids (such as serum, plasma, urine, etc.). Liquid biopsy is a new technology that is not yet available for most types of cancer. Most currently target lung, breast, ovarian, and prostate cancers, and they are more commonly used in patients with non-small cell lung cancer (NSCLC). Liquid biopsies make it easy to sample tumors, conduct continuous monitoring through repeated sampling, design personalized treatment plans, and screen for treatment resistance. Liquid biopsy products include reagents, kits, etc.
Figure Global Liquid Biopsy Products Market Size (M USD) and CAGR (2024-2033)
2 Liquid Biopsy Products Market Growth Drivers and Restraints
The liquid biopsy market is experiencing significant growth, driven by a multitude of factors. One of the primary drivers is the technological advancements in next-generation sequencing (NGS), which has revolutionized the detection and analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes. The cost-effectiveness of these technologies has made liquid biopsies a viable alternative to traditional tissue biopsies, offering a less invasive method for cancer diagnosis and monitoring.
The benefits of liquid biopsies extend beyond patient comfort; they provide real-time insights into tumor dynamics and response to treatment, enabling personalized medicine approaches. This is particularly important in the context of cancer, where genetic mutations can dictate treatment efficacy. Furthermore, liquid biopsies can be used for early cancer screening, which is crucial for improving survival rates and reducing treatment costs.
Another driver is the increasing awareness and acceptance of liquid biopsies among healthcare providers and patients. As more clinical trials validate the accuracy and reliability of liquid biopsy results, the integration of this technology into standard clinical practice is likely to increase.
Despite the promising outlook, the liquid biopsy market faces several constraints. One of the main challenges is the regulatory landscape, which can be complex and varies across regions. Liquid biopsies require stringent quality control measures and standardized protocols to ensure accuracy and reliability, which are still being developed and implemented globally.
The market also faces the challenge of patient and physician awareness. There is a need for educational initiatives to increase understanding of the benefits and limitations of liquid biopsies, especially in regions where traditional biopsy methods are still the norm.
The sensitivity of liquid biopsies compared to traditional tissue biopsies is another constraint. The low levels of ctDNA or cells in biological samples can limit the use of liquid biopsies in early cancer diagnosis. Additionally, the high costs associated with testing and reimbursement can be a barrier, particularly for smaller healthcare facilities with limited budgets.
Privacy concerns also pose a challenge, as liquid biopsies involve genetic sequencing information that could potentially be misused. This has led to a need for robust data protection measures and clear regulations on the use and storage of such sensitive information.
3 Technological Innovations and Mergers in the Liquid Biopsy Products Market
Technological innovation has been a key driver of the liquid biopsy market. The development of NGS platforms has made it possible to detect low levels of ctDNA in the blood, thereby providing a non-invasive method to monitor treatment response and identify treatment candidates. In addition, the integration of artificial intelligence and machine learning algorithms is enhancing the analytical capabilities of liquid biopsy data, leading to more accurate and actionable insights.
In terms of corporate activities, mergers and acquisitions have played a major role in shaping the liquid biopsy market. These activities have enabled companies to expand their product portfolios, acquire new technologies, and strengthen their market positions. For example, Labcorp’s acquisition of Personal Genome Diagnostics and Guardant Health’s acquisition of Guardant Health AMEA were both strategic moves to enhance their liquid biopsy capabilities.
In addition, the industry has launched new products and services that leverage liquid biopsy technology. For example, Guardant Health’s Guardant360® CDx and Labcorp’s Labcorp Plasma Focus are examples of liquid biopsy tests that have been commercialized to support personalized cancer treatment.
In summary, while the liquid biopsy market is expected to grow due to technological advancements and increasing acceptance, it must deal with regulatory complexity, awareness challenges, and costs. Summary of information on technological innovation and corporate mergers and acquisitions. Technological innovation and corporate mergers and acquisitions play an important role in the drug exchange market. Recent advances in drug exchange technology, especially in the field of next-generation medicines (NGS), have greatly driven the development of the drug exchange market.
NGS technology allows researchers to detect low levels of circulating tumor DNA (ctDNA) in the blood, providing a non-invasive method for real-time monitoring of treatment response and identifying treatment candidates. In addition, the integration of artificial intelligence and machine learning algorithms is enhancing the analysis of liquid exchange data to obtain more accurate and actionable insights.
In terms of corporate activities, mergers and acquisitions have had an important impact on the shape of the liquid exchange market. These activities enable companies to expand their product portfolios, acquire new technologies, and strengthen their market positions. For example, Labcorp’s acquisition of Personal Genome Diagnostics and Guardant Health’s acquisition of AMEA are strategic moves to enhance their liquid outlet capabilities.
In addition, the industry has also launched new products and services that utilize exchanger technology. For example, Guardant Health’s Guardant360® CDx and Labcorp’s Labcorp Plasma Focus are examples of commercialized fluid exchanger tests used to support personalized cancer care.
In summary, while the fluid exchanger market is growing due to technological advancements and a desire to gain, it is challenged to navigate regulatory complexities, awareness costs, and barriers.
4 Global Liquid Biopsy Products Market Size by Type
CTCs are cancer cells that have detached from the primary tumor and are present in the bloodstream, potentially leading to metastasis. In 2024, the CTCs segment is projected to reach a value of $971.51 million, reflecting a significant share in the liquid biopsy market. CTCs are crucial for understanding tumor heterogeneity and predicting therapy response, making them a robust biomarker for cancer progression and metastasis assessment.
ctDNA, derived from tumor cells circulating in the blood, contains the genetic code that controls cellular behavior. In 2024, the ctDNA segment is expected to dominate the market with a value of $1561.30 million. ctDNA serves as a non-invasive cancer biomarker, offering an alternative to traditional tissue biopsies. Its potential for real-time monitoring of treatment response and identification of therapeutic candidates’ positions ctDNA as a key player in the liquid biopsy market.
Exosomes are small vesicles released by cells, including cancer cells, into the surrounding biofluids. They contain tumor-derived materials such as DNA, RNA, proteins, lipids, and metabolites. The exosomes segment, while smaller compared to CTCs and ctDNA, is projected to reach $223.24 million in 2024. Exosomes show great promise as novel biomarkers in liquid biopsies due to their enrichment in body fluids and involvement in numerous physiological and pathological processes.
Table Global Liquid Biopsy Products Market Size and Share by Type in 2024
Type | Market Size (M USD) 2024 | Market Share 2024 |
|---|---|---|
CTCs | 971.51 | 35.25% |
ctDNA | 1561.30 | 56.65% |
Exosomes | 223.24 | 8.10% |
5 Global Liquid Biopsy Products Market Size by Application
Blood samples dominate the liquid biopsy market due to their non-invasive nature and the wealth of information they provide for cancer diagnostics. In 2024, the blood sample segment is projected to reach a revenue of $1994.57 million, accounting for the largest share of the market. This application reduces the time and cost required for diagnosis and is pivotal in the early detection and monitoring of various cancers.
Urine samples offer a less invasive approach to cancer detection and are particularly useful for urological cancers. The urine sample segment is expected to generate a revenue of $347.29 million in 2024. While this segment is smaller compared to blood samples, it holds potential for growth as advancements in technology make urine-based diagnostics more reliable and accessible.
Other biofluids, including but not limited to cerebrospinal fluid and saliva, are emerging as valuable sources for liquid biopsies. In 2024, this segment is forecasted to reach a revenue of $414.19 million. The use of other biofluids expands the scope of liquid biopsies beyond traditional samples, catering to specific clinical needs and research applications.
The liquid biopsy market’s segmentation by application reflects the diversity of diagnostic approaches and the continuous evolution of non-invasive cancer detection methods. As technology progresses, the market is expected to expand, with each application playing a critical role in personalized medicine and precision oncology.
Table Global Liquid Biopsy Products Market Size and Share by Application in 2024
Application | Market Size (M USD) 2024 | Market Share 2024 |
|---|---|---|
Blood Sample | 1994.57 | 72.37% |
Urine Sample | 347.29 | 12.60% |
Other Bio Fluids | 414.19 | 15.03% |
6 Global Liquid Biopsy Products Market Size by Region
North America is expected to lead the global liquid biopsy market in 2024 with a revenue of $1411.26 million. The region’s dominance can be attributed to the presence of key market players, advanced healthcare infrastructure, and a high focus on research and development in precision medicine.
Europe follows North America, with a projected revenue of $744.81 million in 2024. The region’s mature healthcare market and strong regulatory support contribute to the adoption of liquid biopsy technologies, particularly in countries like Germany, the UK, and France.
The Asia-Pacific region is anticipated to show significant growth, with a revenue of $539.08 million in 2024. The growth is driven by increasing cancer prevalence, improving healthcare standards, and a growing focus on personalized medicine, particularly in countries like China, Japan, and India.
South America and the Middle East and Africa are emerging markets for liquid biopsies, with projected revenues of $34.73 million and $26.18 million, respectively, in 2024. These regions face challenges such as limited healthcare resources and infrastructure but offer potential for growth as awareness and accessibility to advanced diagnostic methods improve.
The regional segmentation of the global liquid biopsy market highlights the disparities and potentials in different geographic areas. While developed regions like North America and Europe lead in terms of market revenue, the Asia-Pacific region exhibits promising growth prospects. The market’s expansion in South America and the Middle East and Africa, albeit smaller, signifies the global reach and impact of liquid biopsy technologies in the field of oncology.
Figure Global Liquid Biopsy Products Market Size (M USD) by Region in 2024
7 Global Liquid Biopsy Products Market Analysis by Major Players
7.1 Guardant Health
Company Introduction and Business Overview:
Guardant Health, established in 2012 and headquartered in the USA, is a leading precision medicine company that provides critical insights into disease drivers through advanced blood and tissue tests, real-world data, and AI analytics.
Guardant Health is committed to transforming patient care by offering a range of tests including Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The company aims to address the needs of individuals eligible for cancer screening with its Shield™ test.
Products:
Guardant Health’s product lineup includes the Guardant360, a comprehensive genomic profiling test, and Guardant Reveal, a blood-only liquid biopsy test for minimal residual disease (MRD) assessment.
Market Performance in 2024:
Guardant Health is projected to achieve a revenue of $674.86 million with a gross margin of 62.09%.
7.2 Roche
Company Introduction and Business Overview:
Roche, founded in 1896 and based in Switzerland, is a global leader in pharmaceuticals and diagnostics, dedicated to improving lives by advancing science.
Combining the unique advantages of its pharmaceuticals and diagnostics businesses, Roche has become a leader in personalized medicine, providing targeted treatment plans for each patient. Roche is known for its differentiated medicines in oncology, immunology, and other areas, and is a pioneer in diabetes management.
Products:
Roche offers FoundationOne®Liquid CDx, an FDA-approved companion diagnostic that analyzes over 300 genes from a simple blood draw, making it the most comprehensive FDA-approved liquid biopsy on the market.
Market Performance in 2024:
Roche is expected to generate a revenue of $410.98 million with a gross margin of 61.19%.
7.3 Illumina
Company Introduction and Business Overview:
Illumina, established in 1998 and headquartered in the USA, is a global company that focuses on applying innovative technologies and revolutionary assays to the analysis of genetic variation and function.
Illumina’s mission is to enable studies that were not imaginable a few years ago, helping to realize personalized medicine. The company provides flexible, scalable solutions with industry-leading support and service, focusing on collaborative interactions and rapid delivery of solutions.
Products:
Illumina features ctDNA Research Products such as TruSight Oncology 500 ctDNA Assay, which targets multiple somatic variant types from plasma, including tumor mutational burden and microsatellite instability.
Market Performance in 2024:
Illumina is projected to achieve a revenue of $195.33 million with a gross margin of 62.92%.